Monongalia Health System, Inc. – Trademark Portfolio
Entity Type: 03
Monongalia Health System, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MON HEALTH and M MON HEALTH. The owner is based in Morgantown, WV.
1200 J.D. Anderson Drive
Morgantown, WV 26505
Showing of trademarks Trademarks
Trademark Classifications
Monongalia Health System, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Monongalia Health System, Inc. have?
Monongalia Health System, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 2 cancelled.
What trademark classes does Monongalia Health System, Inc. file in?
Monongalia Health System, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Monongalia Health System, Inc.'s most well-known trademarks?
Monongalia Health System, Inc.'s registered trademark portfolio includes well-known marks such as MON HEALTH and M MON HEALTH. These are among 2 currently registered trademarks in the portfolio.
What is Monongalia Health System, Inc.'s trademark registration success rate?
Monongalia Health System, Inc. has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.